BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10319756)

  • 1. PET in lung cancer.
    Coleman RE
    J Nucl Med; 1999 May; 40(5):814-20. PubMed ID: 10319756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of PET in lung cancer.
    Al-Sugair A; Coleman RE
    Semin Nucl Med; 1998 Oct; 28(4):303-19. PubMed ID: 9800237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of whole-body FDG PET in management of lung cancer.
    Higashi K; Matsunari I; Ueda Y; Ikeda R; Guo J; Oguchi M; Tonami H; Yamamoto I
    Ann Nucl Med; 2003 Feb; 17(1):1-14. PubMed ID: 12691125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
    Graeber GM; Gupta NC; Murray GF
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of positron tomography (PET) in lung cancer].
    Kerik NE; Alexanderson-Rosas E; Fermon-Schwaycer S; Ruíz-Ramírez OL; Alonso-López F
    Gac Med Mex; 2004; 140(5):525-9. PubMed ID: 15559234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18-fluorine fluorodeoxyglucose positron emission tomography with computerized tomography versus computerized tomography alone for the management of solitary lung nodules with diameters inferior to 1.5 cm.
    Divisi D; Di Tommaso S; Di Leonardo G; Brianzoni E; De Vico A; Crisci R
    Thorac Cardiovasc Surg; 2010 Oct; 58(7):422-6. PubMed ID: 20922626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET.
    Gupta NC; Maloof J; Gunel E
    J Nucl Med; 1996 Jun; 37(6):943-8. PubMed ID: 8683316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
    Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M
    Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
    Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
    Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging in lung cancer: positron emission tomography scan.
    Vansteenkiste JF
    Eur Respir J Suppl; 2002 Feb; 35():49s-60s. PubMed ID: 12064681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of positron emission tomography in diagnosing and staging of lung cancer].
    Zhu ZH; Zhou Q; Li LY; Cui RX; Cheng WY; Li YF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):365-8. PubMed ID: 12940078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The value of FDG-PET/CT in the evaluation of patients with a pulmonary nodule and a previous malignant disease].
    Ben-Nun A; Orlovsky M; Best AL; Bar Shalom R
    Harefuah; 2006 Oct; 145(10):713-7, 784, 783. PubMed ID: 17111703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
    Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
    J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of FDG PET/CT in the evaluation of solitary pulmonary lesions - own experience.
    Opoka L; Kunikowska J; Podgajny Z; Szołkowska M; Błasińska-Przerwa K; Burakowska B; Oniszh K; Rudziński P; Bestry I; Roszkowski-Śliż K
    Pneumonol Alergol Pol; 2014; 82(3):198-205. PubMed ID: 24793147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Positron emission tomography in the evaluation of intrathoracic lymphatic extension of non-small cell bronchial cancer. A preliminary study of 30 patients].
    Bury T; Corhay JL; Paulus P; Weber T; D'Harcour JB; Limet R; Rigo P; Radermecker MF
    Rev Mal Respir; 1996 Jul; 13(3):281-6. PubMed ID: 8765921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thoracic FDG PET: state of the art.
    Erasmus JJ; McAdams HP; Patz EF; Goodman PC; Coleman RE
    Radiographics; 1998; 18(1):5-20. PubMed ID: 9460106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan.
    Dewan NA; Shehan CJ; Reeb SD; Gobar LS; Scott WJ; Ryschon K
    Chest; 1997 Aug; 112(2):416-22. PubMed ID: 9266877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mediastinal staging of non-small-cell lung cancer with positron emission tomography.
    Chin R; Ward R; Keyes JW; Choplin RH; Reed JC; Wallenhaupt S; Hudspeth AS; Haponik EF
    Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):2090-6. PubMed ID: 8520780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.